Novo Nordisk is the parent company of a group engaged in the development, production and marketing of pharmaceuticals, biological solutions to industrial problems vitamins, dietary supplements and digestive aids. Co. operates on a worldwide basis in two business segments: Diabetes care: discovery, development, manufacturing and marketing of products within the areas of insulin and delivery systems and oral antidiabetic products OAD . Biopharmaceuticals: discovery, development, manufacturing and marketing of products within the therapy areas haemostasis management NovoSeven , growth hormone therapy, hormone replacement therapy and other products.
Quote | Novo-Nordisk A/S (OTCMKTS:NONOF)
Last: | $143.024 |
---|---|
Change Percent: | 0.66% |
Open: | $142.8 |
Close: | $143.024 |
High: | $145.8 |
Low: | $139.696 |
Volume: | 7,196 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Novo-Nordisk A/S (OTCMKTS:NONOF)
2024-07-02 11:20:47 ET Summary This article will outline nine steps I use to identify the most promising pharmaceutical companies and avoid investment pitfalls. In addition, each of the nine steps will provide examples of various factors and how they influence the assessment of th...
2024-07-02 09:17:30 ET More on Eli Lilly 5 Reasons Eli Lilly Just Keeps Rising Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis) Eli Lilly: The Party Is Probably Nearing The End Lilly in deal with Radionetics Oncology on radiopha...
Message Board Posts | Novo-Nordisk A/S (OTCMKTS:NONOF)
Subject | By | Source | When |
---|---|---|---|
Emylers: NONOF Financials 07/16/2014 14:27:56 Novo-Nordisk A/S Period Ending Dec 31, 2012 Dec 31, 20 | Emylers | investorshangout | 07/16/2014 7:27:52 PM |
chartguy89: NONOF 48.35 Stock Charts $NONOF 1 Month Chart | chartguy89 | investorshangout | 03/09/2014 3:19:04 AM |
chartguy89: NONOF Stock Charts Last: -0.60 Friday, February 28, 2014 at 7:59:51 AM $NONOF 1 | chartguy89 | investorshangout | 02/28/2014 1:00:03 PM |
News, Short Squeeze, Breakout and More Instantly...
Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing . Aspect to receive 75 million US dollars in initial payments and u...
New York City, NY: May 06, 2020 – Published via (Wired Release):- “Market.us presents a new report titled Alkyl Benzyl Dimethyl Ammonium Chloride Market: 2020 Research and New Innovations in Oil and Gas Sector. The prime objective of the report is to offer updates and information...